Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company GlaxoSmithKline plc
DescriptionLipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor
Molecular Target Lipoprotein-associated phospholipase A2 (PLA2G7) (PAFAH) (Lp-PLA2)
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationAlzheimer's disease (AD)
Indication DetailsTreat Alzheimer's disease (AD)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today